Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Passive Immunity Trial For Our Nation (Passiton): Study Protocol For A Randomized Placebo-Control Clinical Trial Evaluating Covid-19 Convalescent Plasma In Hospitalized Adults, Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan D. Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn, Jessica B. Collins, Mark R. Denison, Marjolein De Wit, Sheri L. Dixon, Abhijit Duggal, Terri L. Edwards, Magali J. Fontaine, Adit A. Ginde, Michelle S. Harkins, Thelma Harrington, Estelle S. Harris
Passive Immunity Trial For Our Nation (Passiton): Study Protocol For A Randomized Placebo-Control Clinical Trial Evaluating Covid-19 Convalescent Plasma In Hospitalized Adults, Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan D. Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn, Jessica B. Collins, Mark R. Denison, Marjolein De Wit, Sheri L. Dixon, Abhijit Duggal, Terri L. Edwards, Magali J. Fontaine, Adit A. Ginde, Michelle S. Harkins, Thelma Harrington, Estelle S. Harris
School of Medicine Faculty Publications
Background: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear. Methods: The Passive Immunity Trial for Our Nation (PassITON) is a multicenter, placebo-controlled, blinded, randomized clinical trial being conducted in the USA to provide high-quality evidence on the efficacy of COVID-19 convalescent plasma as a treatment for adults hospitalized with symptomatic disease. Adults hospitalized with COVID-19 with respiratory symptoms for less than 14 days are eligible. Enrolled patients are randomized in a 1:1 ratio to 1 unit (200–399 mL) of COVID-19 convalescent plasma that has …
Successful Clearance Of 300 Day Sars-Cov-2 Infection In A Subject With B-Cell Depletion Associated Prolonged (B-Deap) Covid By Regen-Cov Anti-Spike Monoclonal Antibody Cocktail, Arnaud C. Drouin, Marc W. Theberge, Sharon Y. Liu, Allison R. Smither, Shelby M. Flaherty, Mark Zeller, Gregory P. Geba, Peter Reynaud, W. Benjamin Rothwell, Alfred P. Luk, Di Tian, Matthew L. Boisen, Luis M. Branco, Kristian G. Andersen, James E. Robinson, Robert F. Garry, Dahlene N. Fusco
Successful Clearance Of 300 Day Sars-Cov-2 Infection In A Subject With B-Cell Depletion Associated Prolonged (B-Deap) Covid By Regen-Cov Anti-Spike Monoclonal Antibody Cocktail, Arnaud C. Drouin, Marc W. Theberge, Sharon Y. Liu, Allison R. Smither, Shelby M. Flaherty, Mark Zeller, Gregory P. Geba, Peter Reynaud, W. Benjamin Rothwell, Alfred P. Luk, Di Tian, Matthew L. Boisen, Luis M. Branco, Kristian G. Andersen, James E. Robinson, Robert F. Garry, Dahlene N. Fusco
School of Medicine Faculty Publications
A 59-year-old male with follicular lymphoma treated by anti-CD20-mediated B-cell depletion and ablative chemotherapy was hospitalized with a COVID-19 infection. Although the patient did not develop specific humoral immunity, he had a mild clinical course overall. The failure of all therapeutic options allowed infection to persist nearly 300 days with active accumulation of SARS-CoV-2 virus mutations. As a rescue therapy, an infusion of REGEN-COV (10933 and 10987) anti-spike monoclonal antibodies was performed 270 days from initial diagnosis. Due to partial clearance after the first dose (2.4 g), a consolidation dose (8 g) was infused six weeks later. Complete virus clearance …